ESSA Pharma Inc.
EPIXNASDAQHealthcare
$0.20
$-0.00(-1.85%)
Market Cap$9518449
P/E Ratio—
52W High$6.45
52W Low$0.18
ESSA Pharma Inc. (EPIX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EPIX · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2025Report Date: Aug 13, 2025EPS Actual
-$0.09
Est. -$0.17 · +47.1%
Revenue
—
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Aug 13, 2025
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
EPIX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | May 6, 2026 | — | — | — | — | — | — |
| ◌ Q4 FY2025 | Dec 16, 2025 | — | — | — | — | — | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.17 | -$0.09 | +47.1% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.19 | -$0.14 | +26.3% | — | — | — |
| ▼ Q1 FY2025 | Feb 11, 2025 | -$0.18 | -$0.19 | -5.6% | — | — | — |
| ▲ Q4 FY2024 | Dec 17, 2024 | -$0.19 | -$0.14 | +26.3% | — | — | — |
| ▲ Q3 FY2024 | Aug 5, 2024 | -$0.26 | -$0.16 | +38.5% | — | — | — |
| ▼ Q2 FY2024 | May 14, 2024 | -$0.19 | -$0.20 | -5.3% | — | — | — |
Q2 FY2026
May 6, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Dec 16, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.17
EPS Surpr.
+47.1%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.14
EPS Est.
-$0.19
EPS Surpr.
+26.3%
Revenue
—
Q1 FY2025
Feb 11, 2025Miss
EPS Actual
-$0.19
EPS Est.
-$0.18
EPS Surpr.
-5.6%
Revenue
—
Q4 FY2024
Dec 17, 2024Beat
EPS Actual
-$0.14
EPS Est.
-$0.19
EPS Surpr.
+26.3%
Revenue
—
Q3 FY2024
Aug 5, 2024Beat
EPS Actual
-$0.16
EPS Est.
-$0.26
EPS Surpr.
+38.5%
Revenue
—
Q2 FY2024
May 14, 2024Miss
EPS Actual
-$0.20
EPS Est.
-$0.19
EPS Surpr.
-5.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q2 FY2026 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q1 FY2026 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q4 FY2025 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q3 FY2025 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Q2 FY2025 | $-0.17 | $-0.17 | $-0.17 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q3 FY2025 | Aug 13, 2025 | +47.1% | $1.91 | $1.92 | +0.52% |
| ▲ Q2 FY2025 | May 8, 2025 | +26.3% | $1.73 | $1.71 | -1.16% |
| ▼ Q1 FY2025 | Feb 11, 2025 | -5.6% | $1.66 | $1.61 | -3.01% |
| ▲ Q4 FY2024 | Dec 17, 2024 | +26.3% | $1.63 | $1.64 | +0.61% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +38.5% | $4.72 | $4.63 | -1.91% |
| ▼ Q2 FY2024 | May 14, 2024 | -5.3% | $5.93 | $6.00 | +1.18% |
| ▲ Q1 FY2024 | Feb 13, 2024 | +17.6% | $9.67 | $9.65 | -0.21% |
| ▲ Q4 FY2023 | Dec 12, 2023 | +45.5% | $5.35 | $5.50 | +2.80% |
Q3 FY2025+0.52%
Report Date
Aug 13, 2025
EPS Beat/Miss
+47.1%
Price Before
$1.91
Price After
$1.92
Q2 FY2025-1.16%
Report Date
May 8, 2025
EPS Beat/Miss
+26.3%
Price Before
$1.73
Price After
$1.71
Q1 FY2025-3.01%
Report Date
Feb 11, 2025
EPS Beat/Miss
-5.6%
Price Before
$1.66
Price After
$1.61
Q4 FY2024+0.61%
Report Date
Dec 17, 2024
EPS Beat/Miss
+26.3%
Price Before
$1.63
Price After
$1.64
Q3 FY2024-1.91%
Report Date
Aug 5, 2024
EPS Beat/Miss
+38.5%
Price Before
$4.72
Price After
$4.63
Q2 FY2024+1.18%
Report Date
May 14, 2024
EPS Beat/Miss
-5.3%
Price Before
$5.93
Price After
$6.00
Q1 FY2024-0.21%
Report Date
Feb 13, 2024
EPS Beat/Miss
+17.6%
Price Before
$9.67
Price After
$9.65
Q4 FY2023+2.80%
Report Date
Dec 12, 2023
EPS Beat/Miss
+45.5%
Price Before
$5.35
Price After
$5.50
Avg Beat Reaction+0.11%
Avg Miss Reaction-0.91%
Beat Rate6 / 8 quarters
Largest Move-3.01% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EPIX ends December
ESSA Pharma Inc. (EPIX) most recently reported earnings on August 13, 2025 for Q3 FY2025, posting EPS of $-0.09 — beating the analyst consensus of $-0.17 by +47.1%. EPIX has beaten EPS estimates for 2 consecutive quarters. The next EPIX earnings date is expected around September 1, 2026.
Each quarter, investors track EPIX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EPIX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EPIX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EPIX earnings · 5 questionsESSA Pharma Inc.'s next earnings report is expected around September 1, 2026. EPIX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EPIX historically reports after market close (AMC).
EPIX earnings datewhen is EPIX earningsEPIX next earnings datewhen does EPIX report earningsEPIX earnings calendar
▸ Source: FMP · ESSA Pharma Inc. SEC filings · US GAAP · ESSA Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026